887425-47-0

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-BROMOPYRIMIDIN-2-YL)-4-PIPERIDINOL is used as a building block for the synthesis of various pharmaceuticals due to its ability to contribute to the development of new drugs with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(5-BROMOPYRIMIDIN-2-YL)-4-PIPERIDINOL is utilized as a component in the creation of agrochemicals, potentially enhancing crop protection and management strategies.
Used in Medicinal Chemistry:
1-(5-BROMOPYRIMIDIN-2-YL)-4-PIPERIDINOL is employed as a synthetic intermediate in medicinal chemistry, facilitating the discovery and design of novel compounds with significant pharmacological activity.
Used in Organic Synthesis:
As a reagent in organic synthesis, 1-(5-BROMOPYRIMIDIN-2-YL)-4-PIPERIDINOL is used for the creation of heterocyclic compounds, which are important in various chemical and biological applications.

InChI:InChI=1/C9H12BrN3O/c10-7-5-11-9(12-6-7)13-3-1-8(14)2-4-13/h5-6,8,14H,1-4H2

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 32779-36-5 5-Bromo-2-chloropyrimidine 

Downstream Products

• 1279030-58-8 tert-butyl {2-[{3-[2-(4-hydroxypiperidin-1-yl)pyrimidin-5-yl]benzyl}(methyl)amino]-2-oxoethyl}carbamate 

Relevant academic research and scientific papers

BRAF DEGRADERS

Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

Monocycle gyrase and topoisomerase IV inhibitor

The invention belongs to the technical field of medicines, and in particular relates to a gyrase and topoisomerase IV inhibitor compound of formula (I) as shown in the specification, and a pharmaceutically acceptable salt, an ester or stereoisomers thereo

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

NOVEL PYRROLOY2,3-d¨PYRIMIDINE COMPOUND

Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group repre

GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and